Overview

Leflunomide in Rheumatoid Arthritis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study objectives: - To provide more insight on the modulation of inflammation and matrix degrading factors in serum and urine by leflunomide in early , active patients with RA and to validate the sensitivity of DEMRI (Dynamic Enhanced Magnetic Resonance Imaging) in detecting inflammatory changes in active RA in response to treatment with leflunomide - Effect of leflunomide therapy on physical function improvement and Quality of life
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Leflunomide